R&D Commercialization Initiatives

ACT Program
Program Objective
To facilitate entry into clinical trials and improve the success rate of drug development, this program provides tailored consulting through partnerships with drug development experts and clinical specialists by therapeutic area. The goal is to deliver optimal nonclinical and clinical development strategies.
Program Details
  • Program Period: Mar-Dec, 2026 (3-5 months/project)

① Clinical consultation across therapeutic areas: Consultation on clinical entry strategies, analysis of unmet clinical needs for target diseases and patient populations, early clinical trial strategy, protocol design, and more.


② Drug Development Expert Consultation: Advice regarding nonclinical research strategy, toxicology assessment, DMPK-related topics, consultation on efficacy evaluation model development and utilization, early clinical trial strategy, and dose-setting strategy, etc.


③ Clinical Development Plan (CDP) development and strategic clinical development directions: Consultation on indication selection, Target Product Profile (TPP), regulatory (IND) strategy, and clinical development strategy, etc.

Contact

R&D Enabling & Strategy Team: rnd_project@kddf.org